Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zackery P Bulman

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
The Journal of Antimicrobial Chemotherapy|March 13, 2025
Pharmacodynamic assessment of apramycin against Mycobacterium abscessus in a hollow fibre infection modelNidhi Singh, Bikash Dangi, Jeremy J Johnson, et al.
International Journal of Antimicrobial Agents|December 10, 2016
In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection modelRachel L Soon, Justin R Lenhard, Zackery P Bulman, et al.
Computational and Structural Biotechnology Journal|August 11, 2022
Ceftazidime-avibactam based combinations against carbapenemase producing <i>Klebsiella pneumoniae</i> harboring hypervirulence plasmidsZackery P Bulman, Xing Tan, Ting-Yu Chu, et al.
Infectious Diseases and Therapy|December 10, 2015
Optimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaPhillip J Bergen, Zackery P Bulman, Cornelia B Landersdorfer, et al.
Antimicrobial Agents and Chemotherapy|January 6, 2016
Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor CombinationsRachel L Soon, Justin R Lenhard, Zackery P Bulman, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2015
Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin ExposureJustin R Lenhard, Tanya Brown, Michael J Rybak, et al.
The Journal of Antimicrobial Chemotherapy|May 16, 2017
Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coliNicholas M Smith, Zackery P Bulman, Arthur O Sieron, et al.
Infectious Diseases (London, England)|January 25, 2017
A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA)Iffat Shafiq, Zackery P Bulman, Sarah L Spitznogle, et al.
Antimicrobial Agents and Chemotherapy|February 4, 2026
Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-β-lactamase-producing <i>Klebsiella pneumoniae</i>Arunkumar Karunanidhi, Nidhi Singh, Jackson V Watkins, et al.
Antimicrobial Agents and Chemotherapy|January 3, 2024
Improved characterization of aminoglycoside penetration into human lung epithelial lining fluid via population pharmacokineticsEunjeong Shin, Yongzhen Zhang, Jieqiang Zhou, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
The Journal of Antimicrobial Chemotherapy|March 13, 2025
Pharmacodynamic assessment of apramycin against Mycobacterium abscessus in a hollow fibre infection modelNidhi Singh, Bikash Dangi, Jeremy J Johnson, et al.
International Journal of Antimicrobial Agents|December 10, 2016
In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection modelRachel L Soon, Justin R Lenhard, Zackery P Bulman, et al.
Computational and Structural Biotechnology Journal|August 11, 2022
Ceftazidime-avibactam based combinations against carbapenemase producing <i>Klebsiella pneumoniae</i> harboring hypervirulence plasmidsZackery P Bulman, Xing Tan, Ting-Yu Chu, et al.
Infectious Diseases and Therapy|December 10, 2015
Optimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaPhillip J Bergen, Zackery P Bulman, Cornelia B Landersdorfer, et al.
Antimicrobial Agents and Chemotherapy|January 6, 2016
Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor CombinationsRachel L Soon, Justin R Lenhard, Zackery P Bulman, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2015
Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin ExposureJustin R Lenhard, Tanya Brown, Michael J Rybak, et al.
The Journal of Antimicrobial Chemotherapy|May 16, 2017
Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coliNicholas M Smith, Zackery P Bulman, Arthur O Sieron, et al.
Infectious Diseases (London, England)|January 25, 2017
A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA)Iffat Shafiq, Zackery P Bulman, Sarah L Spitznogle, et al.
Antimicrobial Agents and Chemotherapy|February 4, 2026
Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-β-lactamase-producing <i>Klebsiella pneumoniae</i>Arunkumar Karunanidhi, Nidhi Singh, Jackson V Watkins, et al.
Antimicrobial Agents and Chemotherapy|January 3, 2024
Improved characterization of aminoglycoside penetration into human lung epithelial lining fluid via population pharmacokineticsEunjeong Shin, Yongzhen Zhang, Jieqiang Zhou, et al.
Pageof 6